Ranked Top 9 Globally for Solar Trackers: Antaisolar Enters Wood Mackenzie's List, Leading Markets in Multiple Countries
XIAMEN, China, June 10, 2025 /CNW/ -- Recently, the internationally renowned energy consultancy Wood Mackenzie officially released its Global Solar PV Tracker Market Share Report 2025. According to the report, Antaisolar has been ranked 9th globally in the 2024 annual Global solar PV tracker market. In key regional markets such as Latin America, Asia-Pacific, and China, the company secured a position within the Top 6, demonstrating its strong market competitiveness and growing brand influence.
The report notes that global solar tracker shipments reached 111 GW in 2024, marking a 20% year-on-year increase and surpassing the 100 GW milestone for the first time. In this rapidly growing market, Antaisolar delivered 2.55 GW of solar tracker systems worldwide in 2024, representing a 40% year-on-year growth—outpacing the industry average.
Thanks to the stability and reliability of its products and services, Antaisolar has achieved impressive rankings in multiple countries: 4th in India, 5th in Brazil, 6th in China, and 8th in Spain. These accomplishments highlight the company's strategic depth and targeted breakthroughs in key regional markets, continuing its contributions to the global green energy transition.
Since 2006, Antaisolar has been deeply dedicated to the field of solar tracking systems. It has built a comprehensive one-stop service system covering product design, manufacturing, and after-sales support, providing efficient and intelligent solutions to clients worldwide. Its flagship products— TAI-Simple (1P single-axis) and TAI-Universal (2P single-axis)—have been widely adopted in utility-scale projects. The company is set to unveil its new flagship tracker system at the upcoming SNEC exhibition: AT–Spark 1P Multi-Slew Mechanical Linkage Single-Axis Independent Solar Tracking System. Featuring Antaisolar's self-developed large-radius octagonal torque tube combined with dual spherical bearing architecture, it supports ultra-long arrays with large-span multi-string configurations. Combined with Antaisolar SmartTrail intelligent tracking control system—with four layers of extreme weather protection, it ensures optimal performance in challenging conditions such as high winds and snow. Through advanced algorithms that optimize solar irradiance tracking, AT-Spark significantly enhances energy yield and reduces the levelized cost of electricity (LCOE), further solidifying Antaisolar's position as the preferred solution provider for utility-scale PV power plants.
Looking ahead, Antaisolar remains its mission "Raise a Green World" and continues to position itself as an expert in digital intelligent PV mounting system solutions, Antaisolar will continue to write a new chapter of excellence and contribute long-lasting momentum to the global energy transition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Cision Canada
an hour ago
- Cision Canada
Minco Silver Announces Voting Results of 2025 Annual General Meeting of Shareholders
VANCOUVER, BC, June 20, 2025 /CNW/ - Minco Silver Corporation (the "Company" or "Minco Silver") (TSX: MSV) (OTCQX: MISVF) (WKN: A0ESX5) is pleased to announce the voting results of its 2025 Annual General Meeting of Shareholders held today in Vancouver, British Columbia (the "Meeting"). All matters outlined in the Company's Management Information Circular dated May 14, 2025 (the "Information Circular") were approved by shareholders. The number of directors was set at four (4), and all director nominees were duly elected to serve until the next annual meeting of shareholders or until their successors are appointed. The detailed voting results for the election of directors are as follows: Shareholders also approved the following resolutions: 99.95% in favour of setting the number of directors at four; 99.95% in favour of appointing MSLL CAP LLP, Chartered Accountants, as auditors for the ensuing year; and 99.93% in favour of transacting other business as described in the Information Circular. Detailed voting results are available in the Report of Voting Results filed under the Company's profile on SEDAR+ on June 20, 2025. About Minco Silver: Minco Silver Corporation (TSX: MSV / OTCQX: MISVF / WKN: A0ESX5) is a Canadian public company focused on the exploration and development of high-potential mineral resource projects. The Company's flagship assets include the Fuwan Silver Project and the Changkeng Gold Project, both located approximately 45 kilometres southwest of Guangzhou City, China. Minco Silver continues to evaluate and pursue new acquisition opportunities to enhance long-term shareholder value.
Cision Canada
an hour ago
- Cision Canada
Québec and California will hold a joint cap-and-trade emissions units auction on August 20, 2025 Français
QUÉBEC, June 20, 2025 /CNW/ - The Ministère de l'Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs (MELCCFP) and the California Air Resources Board (CARB) announce that the next joint carbon market auction will be held on August 20, 2025. The publication of the Auction Notice, which includes the number of emission units for sale, minimum prices and application requirements, marks the beginning of the application period. The application period closes on July 21, 2025. Associated link: The August 20, 2025 Joint Cap-and-Trade Auction #44 Notice is available on the MELCCFP's website: Source and information : Media Relations Ministère de l'Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs Tél. : 418 521-3991
